Left ventricular non-compaction (LVNC) is a cardiomyopathy that may be of genetic origin; however, few data are available about the yield of mutation, the spectrum of genes and allelic variations. The aim of this study was to better characterize the genetic spectrum of isolated LVNC in a prospective cohort of 95 unrelated adult patients through the molecular investigation of 107 genes involved in cardiomyopathies and arrhythmias.
and to genetic cardiomyopathies by the American Heart Association. 3 The prevalence of LVNC was estimated at 0.014% to 1.3% depending on the age of patients. 4, 5 Multiple imaging techniques are usually useful for the diagnosis of LVNC, with variable echocardiographic or magnetic resonance imaging (MRI) diagnostic criteria but no clear consensus so that the positive diagnosis may be challenging. 6 The phenotypic expression and evolution of isolated LVNC is highly variable, and clinical features can range from asymptomatic to symptomatic, with a relatively stable course over several years or an evolution toward severe complications including congestive heart failure, ventricular arrhythmia, and sudden cardiac death, atrial arrhythmias and systemic embolic events. 6 LVNC is supposed to be related to a premature arrest of compaction of the loose myocardial meshwork during fetal embryogenesis, with persistent trabeculated myocardium, but the precise pathophysiology remains poorly understood. A family history is noticed in a significant proportion of patients and predominant mode of inheritance is autosomal dominant, with some cases with an X-linked transmission. 7 Several genes have been identified as LVNC disease causing. The first reported genetic cause of isolated LVNC was described by Bleyl et al with mutations in the X-linked TAZ gene, also responsible for Barth syndrome. 8 The sarcomere-encoding genes (MYH7, ACTC1, TNNT2, MYBPC3, TMP1, and TNNI3) appear to account for 17% to 30% of LVNC 9,10 but other genes, such as DTNA (α-dystrobrevin), NKX-2.5, Z-line protein-encoding ZASP/LDB3, lamin A/C (LMNA)
genes have been also associated with LVNC. 11 Recently, the TTN gene was also reported as involved in this disease, [12] [13] [14] with a highly heterogeneous prevalence, as high as 19% and the first responsible gene for LVNC in a German study of 68 index cases 13 to 7% in adults but 0% in children from a Dutch cohort of 327 patients. 14 Several studies have analyzed the spectrum of genes in LVNC [9] [10] [11] [12] [13] [14] [15] [16] but with heterogeneous strategies (Sanger or next-generation sequencing [NGS]), usually in retrospective cohorts without imaging core-lab, and usually with a relatively small panel of genes (45 genes in the Dutch study, examination), family history, and tests including ECG, echocardiography, MRI, CT scan, Holter monitoring when available, as well as follow-up data. Only patients with a recent diagnosis of isolated LVNC (maximum in the last 6 months before inclusion) were enrolled. All echocardiographic documents were sent and reviewed by a core lab (Marseille) to confirm the diagnosis. Diagnosis of isolated LVNC was considered definite when several criteria were present in left ventricle (LV): (a) multiple trabeculations with deep endomyocardial recesses, (b) two-layer myocardial structure with a thin compacted (C) and a thick non-compacted (NC) layer, (c) color Doppler evidence of perfused intertrabecular recesses, (d) systolic NC/C ratio >2 (parasternal short-axis view), and (e) no associated heart disease. 17 Cardiac MRI was also frequently performed in our series, with a NC/C ratio of >2.3 in diastole as the recommended threshold for the diagnosis of LVNC using this technique. 18 However, for the purpose of the current study, only the echocardiographic criteria were used as inclusion criteria. Table S1 ). The targeted regions were sequenced using the Illumina MiSeq platform on a 500 cycle Flow Cell (Illumina, Santa Cruz, California) and MiSeq Software generates FASTQ format files after demultiplexing patients' sequences.
| Bioinformatics pipeline
In presence of overlapping paired-end reads, these were merged with Flash. 19 Merged single reads and paired-end reads were then aligned on Hg19 human reference genome using BWA-MEM. 20 This was further followed by a local realignment around insertion and/or deletions and a quality base recalibration by using the GATK program. 21 Polymerase chain reaction (PCR) and optical duplicates were highlighted with the MarkDuplicates Picard tool (http://broadinstitute.github.io/picard) and were further removed using samtools. 22 Resulting .bam outputs from merged single reads and properly paired-end reads were then combined into a unique .bam file. Variant calling was performed using the GATK Haplotype Caller program 21 simultaneously on all sequenced samples.
Detected variants were then annotated using ANNOVAR 23 and CADD 24 tools. Coverage statistics were produced using the HsMetrics Picard tool. Detected variants with sequencing depth greater than 30X
and with at least 20% of reads supporting the alternative allele were kept for analysis. Detection of copy number variation (CNV) was performed after coverage normalization, by computing the ratio of a target's coverage of a given individual over the mean coverage of this target across all patients of the same sequencing run.
| Variants interpretation
Pathogenicity of variants was determined according to current ACMG guidelines 25 3 | RESULTS
| Patients
Ninety-five unrelated patients ranging from 19 to 81 years old were included in the study with a mean age at diagnosis/inclusion of 46.3 (AE15) years old. This cohort was composed of 56 males and 39 females. At the time of inclusion, 46 patients had an NYHA score > 1, mean ejection fraction at inclusion was 42.5% (AE14.5) and mean heart rate was 68.5 bpm (AE15.6). Clinical characteristics of index patients were summarized in Table 1 . 
| Performance of the custom panel

| Allelic Spectrum
Cohort analysis led to the identification of 52 confirmed or highly sus- , and a CNV consisting in a complete deletion of RYR2 exon 3 (Table 3 ).
In the second prevalent gene HCN4, 5 different missense variants were found including one already published in LVNC. These variants were located in the transmembrane domain 4 (c.1123C > T, p.
Arg375Cys), in the pore (c.1403C > T, p.Ala468Val, c.1438G > T, p.
Gly480Cys and c.1444G > A, p.Gly482Arg) and before the transmembrane domain 5 (c.1231C > G, p.Leu411Val). (Table 3 ).
In order to classify genes and variants according to their function in the cardiomyocytes, we defined 5 cellular "compartments"
( Figure 1 ). The distribution of the 52 variants in the 23 genes showed that 52% of variants (N = 27) were located in sarcomeric genes, 21%
(N = 11) were in ion channel or related genes, 8% (N = 4) were in genes involved in the cellular structure, and 6% (N = 3) were located in desmosome genes. In addition, 12% of variants (N = 6) were found in transcription factors genes or genes involved in other structures or functions (eg, NKX2-5).
Finally, upon the 52 identified variants, 40 were located in the 13 already known LVNC genes (77%) and 12 were located in the 10 additional candidate genes (23%) ( Tables 2 and 3 ).
| Multiple mutations in patients
In the cohort, nine patients (9.5%) presented a complex genotype feature with the presence of more than one pathogenic variant. Seven patients harbored two disease-causing variants in cardiomyopathy genes ( Figure 2 ) and two patients carried at least three pathogenic variants: one with BAG3, MYH7, and NKX2-5 variants and the second with ACTC1, ANK2, LDB3, and MYLK2. Regarding the TTN gene, eight patients were carrying a unique TTN variant and two patients carried a TTN mutation associated with another gene variant (MYH6, NEXN).
| Mutations, patients and phenotype
According to our variant selection criteria, a pathogenic variant was identified in 40 patients of the cohort (20 males and 20 females; 50%), including 31 patients (32.5%) with single variant and 9 patients with complex genotypes (9.5%). TTN mutations are predominant and identified in 10 patients of the cohort (10.5%). In 55 patients (58%), no genetic cause was identified. Fifteen patients had a known family history of LVNC, 55 patients were sporadic cases and family history was not available for 25 patients. Among these groups, the mutation rate is 53%, 46%, and 28%, respectively. The difference between familial cases and sporadic cases is not significant (p = 0.77). In two families, segregation analysis was performed. In family 1 mutated in HCN4, four relatives were carriers of the mutation, two affected with LVNC associated with bradycardia and two with isolated bradycardia.
In family 2, mutated in RYR2, two affected members with LVNC were carriers of the mutation (Figure 3 ).
An analysis was performed regarding the age at diagnosis, ejection fraction, the presence of dyspnea (NYHA>1) and heart rate comparing the groups of mutated patients vs patients with no identified genetic cause. Mutated patients tended to be younger at diagnosis (43.0 vs 48.7 years, p = 0.07) but systolic dysfunction showed no significant difference between groups (Table 4) . Interestingly, the mutation yield was higher in youngest patients <65 years old (38/84, 45%)
as compared to oldest patients >65 years (2/11, 18.2%, p = 0.11). Patients with complex genotypes (≥2 mutations), as compared to patients with single variants, tended to be younger at diagnosis and to have a decreased ejection fraction although differences were not significant (Table 4) . Finally, in patients carrying a single variant, we observed that the LV mean ejection fraction in patient with a mutation in sarcomeric genes (N = 18) was lower than in patients mutated in non-sarcomeric genes (N = 13) (43.8% vs 51.6%, p = 0.26).
| DISCUSSION
We present here the results of the genetic analysis of a cohort of 95 independent patients (index cases) with LVNC to evaluate the yield of mutation screening and to assess the allelic and genetic spectrum of the disease. The design of our study has some characteristics that may differ from previous studies because our project was a prospective study performed in newly diagnosed consecutive patients (diagnosis less than 6 months) with a validation of the cardiac diagnosis by an expert centralized imaging core-lab. This design was conceived to limit potential inclusion bias and strengthen the representativeness of the cohort. We also focused on isolated LVNC, without associated congenital heart defects, in adult patients to have a more homogeneous population. NGS was performed with a panel of 107 genes involved in cardiomyopathies and some arrhythmias, which represents the most comprehensive genetic analysis published (exome sequencing was performed by Sedagast-Hamedani et al. but only selected genes known to be involved in the phenotype were reported). 13 When considering pathogenic or likely pathogenic variants, we identified a mutation in 42% of the patients, which represents a proportion slightly higher than previously reported in this disease ,9,10,13,14,16 but relatively similar to features observed in other cardiomyopathies. 28 The distribution of genes revealed a high degree of genetic heterogeneity with putative or confirmed pathogenic mutations identified in 23 different genes. The distribution includes 13 genes previously published as associated with the phenotype of LVNC (77% of variants) and 10 additional candidate genes (9 cardiomyopathy and 1 arrhythmia genes) that were never reported before as associated with LVNC (Table 1) The following most prevalent genes were HCN4 and MYH7, followed by MYH6, RYR2, and ACTC1. Considering others published reports, 13,14 some discrepancies were observed in the gene distribution especially regarding TTN, MYH7, HCN4, and LMNA. Differences in distribution may be related in part to the variable characteristics of the cohorts (isolated LVNC or not, age at diagnosis, incident or prevalent cases). We observed a relatively high proportion of patients with HCN4 pathogenic variants as we found 5 different variants, located in S4, S5 and pore domains of the protein (Table 2 ). Among these patients 3/5 presented bradycardia (one patient was implanted by a pace maker) but no valvular disease has been reported in any of them. 29, 30 This suggests that this recently published gene 29 constitutes an important disease-causing gene in LVNC. The prevalence of HCN4 did not appear as such in previously published cohorts, possibly because of the absence of this gene in some studied panels [9] [10] [11] 14, 15 or a difference in the cohort recruitment. 13, 16 For other genes, a higher rate of MYH7 variants and a lower rate of LMNA variants were found in our cohort as compared with the study of SedaghatHamedani et al 13 while frequency of TTN and MYBPC3 variants were consistent. In the work of van Waning et al, 14 the proportion of MYH7
and MYBPC3 in the group of adult patients were consistent with us but a lower rate of TTN variants was observed. In older publications 9,10 in which only sarcomeric genes were analyzed, the spectrum of genes showed that MYH7 was the most prevalent gene then TNNT2, TMP1, and TNNI3. These last three genes were not found mutated in our cohort, which could be because of the fact that our cohort is composed by patients with an adult onset of the disease.
Interestingly, our results also strengthen the involvement of recently published genes, such as HCN4 29, 30 and RYR2 31 and help to better estimate their prevalence. As a whole, our finding about the large genetic and allelic spectrum is helpful in refining the genes of interest for routine molecular diagnostic of patients with LVNC.
In addition, we tried to determine if patients reporting a familial history of LVNC, were more frequently found with a mutation than patients presenting as sporadic cases. The cohort includes 15 familial form and 55 sporadic cases, the 25 remaining patients had no information's about their relatives. Quite the same rate of mutation identification was found in the group of familial forms and sporadic cases (53% and 46% respectively, difference not significant)."
Apart from the report of mutations in genes previously associated with LVNC, an important finding of our study is that we identified mutations in 10 genes known to be involved in cardiac inherited diseases but not described until now as associated with this specific phenotype. Among these genes, nine were previously reported as associated with other sub-types of cardiomyopathy, such as HCM, DCM, and ARVC (Table 1) , suggesting an overlap between the various cardiomyopathies. Among these 10 genes, MYLK2 and NEXN were identified each in 2 patients and 7 genes (BAG3, FLNC, HEY2, MYPN, PDLIM3, TMEM43, and DSC2) were involved each in only one patient. Although these genes could be good candidates for being pathogenic, the definitive role of these genes for causing LVNC will was never reported before in LVNC, cautious is necessary before any conclusion about the causal role of these variants. However, HCN4 was initially described in channelopathies and then involved in LVNC ,29,30 with a significant proportion in our cohort, illustrating the fact that a given gene involved in arrhythmias does not preclude the potential role in LVNC.
Another observation emerging from this study is the high level of patients (9.5%) presenting complex genotypes with causative variants in two (or more) different genes. This feature about double mutated patients was not previously described as so high in adult patients with LVNC. In patients with complex genotypes, cumulative effect of variants have been associated with a higher severity of the disease in one study 14 
| Limitations
Our results were derived from a cohort of adult-onset patients with isolated LVNC. Therefore, results may not be applicable to a pediatric population or a population with syndromic LVNC. Even though probably pathogenic variants completed all the criteria for pathogenicity, we do no't provide family segregation and functional analysis for now.
In conclusion, molecular analysis of 107 genes in 95 adult patients with isolated LVNC shows a mutation detection rate of 42%. These data, coming from the most comprehensive study available until now in terms of genes that were analyzed, show that LVNC is basically a genetic disease in most cases, with a large genetic heterogeneity. The global distribution of genes appears quite close to the profile observed in DCM patients, with TTN as the most frequent mutated gene, but with some specific genes such as HCN4. We found 9.5% of patients presenting a complex genotype with a disease-causing variant in two different genes located on different chromosomes. This observation could explain part of intra-familial variable expressivity in case of bilineal inheritance, as some relative should be carrier of a single variant with a moderate phenotype. We also described mutations in 10 genes not described until now as associated with LVNC. Although these genes are putative good candidates for causing LVNC, the definitive causal role of these genes in this phenotype will require confirmation in further studies. 
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